Anthropic Establishes Wet Lab, Deploys Claude for Automated Experiments

Anthropic has established an in-house biological wet laboratory in the San Francisco Bay Area, marking a strategic pivot to accelerate its artificial intelligence-driven drug discovery pipeline. First reported on September 18, the facility addresses a critical bottleneck in AI for Science: the widening gap between rapid computational design and physical experimental validation. Eric Kauderer-Abrams, Anthropic’s life sciences lead, confirmed that the company is integrating Claude directly into real-world biological testing. While external partners continue to handle select assays, the new laboratory enables Anthropic to maintain tighter control over the design-build-test-learn cycle. Recent proprietary experiments demonstrate tangible progress, with Claude’s protein design models achieving success rates above twenty percent across fifteen biological targets, surpassing conventional design benchmarks. However, scaling validation through third-party providers introduces scheduling delays and rising costs, as reflected in recent order surges at partner organizations like Twist Bioscience. To overcome hardware fragmentation, Anthropic developed the Model Hardware Standard, an interoperability protocol that unifies control over diverse laboratory instrumentation. The standard allows AI agents to interface directly with liquid handlers, robotic arms, and microplate readers through a consistent command structure, reducing system integration timelines from months to minutes. In preliminary deployments, Claude has successfully coordinated multi-step biochemical assays, dynamically adjusting parameters based on real-time readouts and autonomously troubleshooting hardware anomalies. Academic collaborations have further validated the framework’s capacity to manage complex workflows, including real-time quantitative PCR monitoring and automated sample transfer sequences. This infrastructure positions Anthropic to transition from computational prediction to closed-loop experimental automation. As AI systems assume greater responsibility for physical laboratory operations, the competitive advantage in drug discovery will increasingly hinge on the velocity and reliability of iterative validation rather than algorithmic throughput alone. The initiative also highlights emerging operational challenges, including equipment safety, material handling protocols, and regulatory oversight as autonomous agents interact directly with biological compounds. By synchronizing computational design with benchtop execution, Anthropic is redefining the parameters of next-generation biotechnology development.